Loading...
Evidence supporting the use of recombinant activated factor VII in congenital bleeding disorders
BACKGROUND: Recombinant activated factor VII (rFVIIa, NovoSeven(®)) was introduced in 1996 for the treatment of hemophilic patients with antibodies against coagulation factor VIII or IX. OBJECTIVE: To review the evidence supporting the use of rFVIIa for the treatment of patients with congenital blee...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2010
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2915535/ https://ncbi.nlm.nih.gov/pubmed/20689697 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|